Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations (Q44980758)
Jump to navigation
Jump to search
scientific article published on 15 July 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations |
scientific article published on 15 July 2004 |
Statements
1 reference
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations (English)
1 reference
Susan Branford
1 reference
Zbigniew Rudzki
1 reference
Ian Parkinson
1 reference
Andrew Grigg
1 reference
Kerry Taylor
1 reference
John F Seymour
1 reference
Simon Durrant
1 reference
Peter Browett
1 reference
Anthony P Schwarer
1 reference
Chris Arthur
1 reference
John Catalano
1 reference
Michael F Leahy
1 reference
Robin Filshie
1 reference
Kenneth Bradstock
1 reference
Richard Herrmann
1 reference
David Joske
1 reference
Kevin Lynch
1 reference
Tim Hughes
1 reference
15 July 2004
1 reference
Identifiers
1 reference